N/A
Completed N=108
Effectiveness of Anti-IL-5/IL5R Inhibitors
Source: ClinicalTrials.gov NCT06239441 ↗Enrolled (actual)
108
Serious AEs
—
Results posted
Oct 2024
Primary outcomePrimary: Response to IL5/IL5R Antagonist — 76.5; 82.5 Percent
Summary
The goal of this observational study is to assess the response to treatment, in patients 18 years and older diagnosed with severe asthma in whom an IL5/IL5R antagonists was initiated between 2012 and 2020.
The main question[s] it aims to answer are:
* What is the response rate after one year of treatment with IL5/IL5R antagonists.
* What is the response and remission rate after one year of treatment with IL5/IL5R antagonists in subjects who fullfilled the original randomized control trials (RCTs) inclusion criteria compared with those who did not.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response to IL5/IL5R Antagonist |
76.5; 82.5 | — |
| PRIMARY Remission Rate With IL5/IL5R Antagonist |
45; 24.4 | — |
Eligibility Criteria
Inclusion Criteria
All patients 18 years and older diagnosed with severe asthma in whom an IL5/IL5R antagonist was initiated at the outpatient asthma clinic of a tertiary center (Sacre-Coeur Hospital) in Montreal.c between 2012 and 2020.
Exclusion Criteria
None
Data sourced from ClinicalTrials.gov (NCT06239441). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.